722538-98-9Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIES
-
Page/Page column 12-13, (2021/09/17)
Provided are Compounds 1-8, and their pharmaceutically acceptable salts or prodrugs thereof. Compounds 1-8 are selective binders to TYK2's JH2 and they exhibit significant inhibitory effects on the physiological function of TYK2 and they have excellent in vivo pharmacokinetic properties. Compounds 1-5 and 7 have several deuterium substitutions on methyl to improve pharmacokinetic (PK) properties.
Heterocyclic compounds as TYK2 inhibitors and methods of synthesis and use
-
Paragraph 0240-0244, (2020/11/23)
The invention provides a heterocyclic compound serving as a TYK2 inhibitor and a synthesis and use method, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as the TYK2 inhibitor. The compounds of the present invention exhibit excellent inhibitory activity against TYK2.
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00424-00425, (2020/06/10)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Wrobleski, Stephen T.,Moslin, Ryan,Lin, Shuqun,Zhang, Yanlei,Spergel, Steven,Kempson, James,Tokarski, John S.,Strnad, Joann,Zupa-Fernandez, Adriana,Cheng, Lihong,Shuster, David,Gillooly, Kathleen,Yang, Xiaoxia,Heimrich, Elizabeth,McIntyre, Kim W.,Chaudhry, Charu,Khan, Javed,Ruzanov, Max,Tredup, Jeffrey,Mulligan, Dawn,Xie, Dianlin,Sun, Huadong,Huang, Christine,D'Arienzo, Celia,Aranibar, Nelly,Chiney, Manoj,Chimalakonda, Anjaneya,Pitts, William J.,Lombardo, Louis,Carter, Percy H.,Burke, James R.,Weinstein, David S.
, p. 8973 - 8995 (2019/11/14)
Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formi
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00341; 00343, (2018/04/27)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
-
Page/Page column 75, (2017/09/02)
Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES
-
Paragraph 00164, (2015/05/26)
Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
-
Paragraph 00224, (2014/05/24)
Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
-
Paragraph 00195, (2014/05/24)
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
